41 results about "Alcohol intake" patented technology

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.

A vehicle control system includes an alcohol detector which detects an alcohol intake level of a driver of a vehicle; and a controller which determines whether the driver is a drunk person based on a detection result obtained from the alcohol detector, and which stops the vehicle when a determination result that the driver is the drunk person is obtained. After a door of the vehicle is switched from a closed state to an open state, and before an operation of a start-up of the vehicle is performed, the controller controls the alcohol detector so that a detection of the alcohol intake level is started, and allows a travelling of the vehicle before the detection result is output from the alcohol detector.

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.

The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.

Provided are compounds having the general structure according to Formula (I):Further provided are pharmaceutical compositions comprising these compounds. The invention still further provides methods of treating alcoholism, methods of reducing alcohol intake, methods of treating anhedonia, and methods of treating anxiety using theses compounds or the compositions containing them.

A brain health food / brain health beverage for preventing / alleviating brain atrophy due to alcohol intake is developed. The brain health food or brain health beverage containing, as active ingredients,folic acid, vitamin B6, and vitamin B12, for preventing a decrease in the brain capacity of regular drinkers who are not suffering from dementia, i.e., healthy people, is characterized by containing,as active ingredients, 0.4-0.8 mg of folic acid, 10-20 mg of vitamin B6, and 0.25-0.5 mg of vitamin B12.

The invention discloses an anti-alcoholic liver injury Atractylodes macrocephala polysaccharide and a preparation method thereof. The Atractylodes macrocephala polysaccharide is composed of glucose, mannose and xylose in a molar ratio of 6.8:3.0:1.0; its molecular weight is 5465 Da; The secondary structure is: βXyl p ‑[(1→3)‑βXyl p ] 6 -(1→6)-αGlc p ‑[(1→4)‑αGlc p ] 40 ‑[(1→2)‑αMan p ] 12 . The experimental results show that: Atractylodes macrocephala polysaccharide has obvious protective effect on acute alcoholic liver injury in mice, can significantly inhibit the increase of serum AST, ALT and TG activities caused by alcohol acute liver injury, and effectively inhibit the alcohol intake-induced The increase of liver index, the increase of MDA content in the liver, and the decrease of SOD and GSH‑Px activities can effectively relieve the symptoms of alcoholic liver injury in mice, which shows that Atractylodes macrocephala polysaccharides have a better effect on alcohol-induced acute liver injury in mice. Good protection.

The invention disclosed herein includes nanocomplexes designed to include enzymes with complementary functional attributes and methods of using these nanocomplexes. Illustrative examples include nanocomplexes comprising both alcohol oxidase and catalase. These nanocomplexes can be used in methods designed to reduce blood alcohol levels in the body and / or break down toxic byproducts of alcohol metabolism. Thus, these nanocomplexes are useful in the treatment of a variety of conditions caused by alcohol intake, including, for example, acute alcoholism.